Cargando…
Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis
Mycobacterium tuberculosis is the causative agent of TB and was estimated to cause 1.4 million death in 2019, alongside 10 million new infections. Drug resistance is a growing issue, with multi-drug resistant infections representing 3.3% of all new infections, hence novel antimycobacterial drugs are...
Autores principales: | Kingdon, Alexander D.H., Alderwick, Luke J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258792/ https://www.ncbi.nlm.nih.gov/pubmed/34285773 http://dx.doi.org/10.1016/j.csbj.2021.06.034 |
Ejemplares similares
-
Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach
por: Ejalonibu, Murtala A., et al.
Publicado: (2021) -
In Silico Strategies in Tuberculosis Drug Discovery
por: Macalino, Stephani Joy Y., et al.
Publicado: (2020) -
In Silico Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis
por: Knoll, Kirsten E., et al.
Publicado: (2022) -
Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach
por: Soto, Ramón, et al.
Publicado: (2018) -
Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase
por: Alderwick, Luke J, et al.
Publicado: (2011)